EUVIMEDEUVIMED entdecken
Crossref

How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?

Aleksander Salomon-Perzyński, Bożena Katarzyna Budziszewska

Hematology in Clinical Practice · 2023

DOI: 10.5603/hcp.2023.0002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology in Clinical Practice, 2023. Verfasst von Aleksander Salomon-Perzyński und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Salomon-Perzyński, A., & Budziszewska, B. K. (2023). How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?. Hematology in Clinical Practice. https://doi.org/10.5603/hcp.2023.0002

Vancouver

Salomon-Perzyński A, Budziszewska BK. How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?. Hematology in Clinical Practice. 2023. doi:10.5603/hcp.2023.0002

BibTeX
@article{SalomonPerzyski2023,
  author = {Salomon-Perzyński, Aleksander and Budziszewska, Bożena Katarzyna},
  title = {How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?},
  journal = {Hematology in Clinical Practice},
  year = {2023},
  doi = {10.5603/hcp.2023.0002}
}
Kostenlos starten →